Magazine
Latest Issue

The two new vaccines give cause for hope—but not carelessness

The Novavax and Johnson & Johnson jabs will help combat Covid 19—but vaccines alone won’t eradicate the virus

By Philip Ball  

Photo: Vladimir Zuev / Alamy Stock Photo

Last week’s addition of two more effective vaccines against Covid-19 was very good news. With fast-spreading and potentially more virulent variants of the virus now on the rampage in many parts of the world, and grim predictions that some developing countries might not get adequate supplies of vaccines before 2023, we need all the prophylactic agents we can get against this pandemic.

But the positive news came with caveats. In particular, the effectiveness of both new vaccines is significantly lower against the fast-spreading South African virus variant denoted B.1.351. A trial of the US biotech company Novavax’s vaccine…

Register today to continue reading

You’ve hit your limit of three articles in the last 30 days. To get seven more, simply enter your email address below.

You’ll also receive our free e-book Prospect’s Top Thinkers 2020 and our newsletter with the best new writing on politics, economics, literature and the arts.

Prospect may process your personal information for our legitimate business purposes, to provide you with newsletters, subscription offers and other relevant information.

Click here to learn more about these purposes and how we use your data. You will be able to opt-out of further contact on the next page and in all our communications.

We want to hear what you think about this article. Submit a letter to letters@prospect-magazine.co.uk

More From Prospect